What is Viking Therapeutics's treasury stock?

Viking Therapeutics (VKTX) reported treasury stock of $0 in Q4 2025.

What is the long-term trend for Viking Therapeutics's treasury stock?

Over 3 years (2022 to 2025), Viking Therapeutics's treasury stock has grown at a -100.0% compound annual growth rate (CAGR), from $6.8M to $0.

Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

PfizerPFE

$115.19B+0.2%

Ultragenyx PharmaceuticalRARE

$10M+32.2%

Sarepta Therapeutics, Inc.SRPT

$25.26M—

Revenue-—

Operating income-$164.1M-196%

Net income-$158.3M-247%

EPS (diluted)-$1.37-234%

Cash & equivalents$118.1M+211%

Total debt$137.0K-87.8%

Total equity$501.9M-40.7%

Total assets$608.2M-29.8%

Operating cash flow-$114.0M-118%

Market cap$4.04B+38.7%

Return on equity-70%-94.5pp

Debt / equity0×0.0×

Current ratio5.7×-38.5×

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockValue.

The official record: Viking Therapeutics’s 10-K, filed February 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Viking Therapeutics's treasury stock?: Viking Therapeutics (VKTX) reported treasury stock of $0 in Q4 2025.
What is the long-term trend for Viking Therapeutics's treasury stock?: Over 3 years (2022 to 2025), Viking Therapeutics's treasury stock has grown at a -100.0% compound annual growth rate (CAGR), from $6.8M to $0.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.